Hospital
Deborah Heart and Lung Center
Deborah Heart and Lung Center was paid $9.53M by Medicaid between Jan 2018 and Nov 2024, across 109 billing codes. Its largest line is 93306, Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete — 32% of everything it billed.
33Billing provider infoDEBORAH HEART AND LUNG CENTER
BROWNS MILLS, NJ 08015
BROWNS MILLS, NJ 08015
33aNPI1467440743assigned 10/11/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.53M
24GClaims209,764
24DCodes billed109
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#61 of 93
Median peer was paid$30.60M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,882 | $1.34M | |
| 2019 | 19,295 | $1.56M | |
| 2020 | 19,639 | $1.22M | |
| 2021 | 25,812 | $1.51M | |
| 2022 | 46,646 | $1.55M | |
| 2023 | 48,074 | $1.32M | |
| 2024incomplete | 34,416 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 32% | 5,374 | 4,958 | $3.07M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 13% | 20,766 | 17,181 | $1.28M |
| 93017 | 11% | 2,430 | 2,226 | $1.08M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.2% | 31,551 | 25,539 | $498K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.6% | 1,802 | 752 | $437K |
| OP279 | 4.6% | 2,424 | 1,878 | $434K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 3.7% | 1,045 | 940 | $356K |
| 94060 | 2.6% | 772 | 743 | $249K | |
| 94010 | 2.0% | 850 | 763 | $191K | |
| 94729 | 1.3% | 1,125 | 1,056 | $125K | |
| 93226 | 1.3% | 461 | 459 | $123K | |
| OP250 | 1.2% | 20,878 | 4,184 | $117K |
97 more codes
| 93225 | 1.1% | 461 | $109K | |
| 71250 | 1.0% | 388 | $98K | |
| 93880 | <1% | 299 | $78K | |
| 93923 | <1% | 261 | $66K | |
| 93356 | <1% | 2,204 | $65K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,482 | $65K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 647 | $63K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,545 | $62K |
| 93296 | <1% | 4,066 | $55K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,156 | $54K |
| 93925 | <1% | 156 | $43K | |
| 93970 | <1% | 85 | $41K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,313 | $40K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 520 | $39K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 3,338 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,554 | $35K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,978 | $35K |
| 94727 | <1% | 373 | $32K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,086 | $31K |
| 93243 | <1% | 616 | $28K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,197 | $26K |
| 94618 | <1% | 498 | $25K | |
| 82962 | <1% | 2,564 | $25K | |
| G0378 | Hospital observation service, per hour | <1% | 176 | $24K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,572 | $23K |
| 80053 | Comprehensive metabolic panel | <1% | 6,191 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,817 | $21K |
| 80061 | Lipid panel | <1% | 4,895 | $20K |
| OP259 | <1% | 8,675 | $19K | |
| 93247 | <1% | 455 | $18K | |
| 93242 | <1% | 613 | $18K | |
| 93304 | <1% | 70 | $15K | |
| 95811 | <1% | 12 | $15K | |
| 85610 | <1% | 5,259 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,270 | $14K |
| C1769 | Guide wire | <1% | 725 | $13K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 13 | $12K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 462 | $12K |
| 93246 | <1% | 452 | $11K | |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | <1% | 339 | $10K |
| 0296T | <1% | 178 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 940 | $9K |
| 87641 | <1% | 1,455 | $8K | |
| 0297T | <1% | 169 | $8K | |
| OP379 | <1% | 296 | $7K | |
| 83880 | <1% | 1,034 | $7K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 32 | $6K |
| 75561 | <1% | 13 | $6K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 412 | $5K |
| 85730 | <1% | 985 | $5K | |
| OP272 | <1% | 193 | $5K | |
| 93297 | <1% | 610 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 142 | $4K |
| 0012A | <1% | 112 | $4K | |
| 0011A | <1% | 115 | $4K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 13 | $4K |
| 0002A | <1% | 111 | $4K | |
| 0001A | <1% | 100 | $3K | |
| 83735 | <1% | 2,801 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 132 | $3K |
| 86850 | <1% | 828 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,447 | $2K |
| 93299 | <1% | 214 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 121 | $2K |
| 93298 | <1% | 147 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,465 | $1K |
| 93289 | <1% | 82 | $1K | |
| 86901 | <1% | 828 | $1K | |
| 84484 | <1% | 254 | $1K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 26 | $982.66 |
| 86900 | <1% | 830 | $805.53 | |
| 93750 | <1% | 47 | $639.04 | |
| 87070 | <1% | 529 | $636.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 208 | $504.78 |
| 84439 | <1% | 255 | $477.59 | |
| 71045 | Radiologic examination, chest; single view | <1% | 59 | $386.80 |
| C1885 | Catheter, transluminal angioplasty, laser | <1% | 13 | $330.29 |
| 93280 | <1% | 33 | $290.94 | |
| 93288 | <1% | 30 | $282.41 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 72 | $200.71 |
| 85347 | <1% | 116 | $135.75 | |
| 87077 | <1% | 78 | $135.12 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 104 | $101.82 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 493 | $101.03 |
| 80076 | <1% | 16 | $81.05 | |
| 87186 | <1% | 16 | $68.82 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 18 | $44.28 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 65 | $37.88 |
| 87205 | <1% | 39 | $23.08 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 41 | $17.47 |
| 82565 | <1% | 14 | $14.61 | |
| 83615 | <1% | 15 | $10.10 | |
| 85027 | <1% | 20 | $5.04 | |
| 84520 | <1% | 18 | $4.00 | |
| 85007 | <1% | 20 | $2.52 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 23 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 76 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHIRICHELLA, JOSEPH (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Professional Service Fund of Deborah Heart & Lung Center | Browns Mills, NJ | $876K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.